An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Epacadostat (Primary) ; Pemigatinib (Primary) ; Retifanlimab (Primary) ; Tuparstobart; Verzistobart
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms POD1UM-204
- Sponsors Incyte Corporation
- 24 Oct 2023 Planned End Date changed from 22 Jun 2025 to 31 May 2026.
- 24 Oct 2023 Planned primary completion date changed from 25 Aug 2023 to 30 Apr 2025.
- 09 Feb 2023 This trial has been Discontinued in Germany (Date of the global end of the trial: 23-Jan-2023), according to the European Clinical Trials Database record.